Skip to main content


Professor David Celermajer has been Group Leader of the Clinical Research Group since 1994 and in 2003 was appointed as Clinical Director of HRI. In 2014, he was appointed as an Officer of the Order of Australia for services as a researcher and clinician in the field of cardiovascular disease. Dr Celermajer’s research areas of expertise include adult congenital heart disease, pulmonary hypertension, clinical cardiology and early origins of atherosclerosis.

David has published over 300 scientific articles, as well as many review and editorial papers, totalling over 900 citations per year. This work includes the development and demonstration of a key ultrasound imaging technique, Flow Mediated Dilatation. This procedure is now used worldwide to measure endothelial function to detect the early onset of vascular diseases such as atherosclerosis. More recently David has been a leading clinician-scientist researching Adult Congenital Heart Disease, an emerging patient group with complex care needs. This work has been highly transitional, David founded DC Devices Pty Ltd (DC Devices Inc in the USA) which aims to commercialise a device for the treatment of Heart Failure.

To succeed as a scientist, passion and commitment are the necessary prerequisites, as one needs to feel that the joy of discovery outweighs the hurdles involved. A good measure of patience is helpful. Most important of all is the ability to think laterally if surprised by an unexpected result — many of the best discoveries are serendipitous!”

Questions about mRNA vaccines and heart...

Get the answers